Prévisions du marché des adjuvants de vaccins en Europe jusqu\'en 2030 - Analyse régionale - par classe d\'adjuvants (adjuvant de sel minéral, adjuvant d\'émulsion, adjuvant de liposome et autres) et type (adjuvant de vaccin humain et adjuvant de vaccin vétérinaire)
Les approbations d\'adjuvants de vaccins vétérinaires stimulent le marché européen des adjuvants de vaccins
La vaccination des animaux contre les maladies courantes reste la méthode la plus efficace au monde pour prévenir les pertes financières et autres dues aux maladies infectieuses dans l\'élevage. Les approbations réglementaires pour les adjuvants de vaccins vétérinaires sont en augmentation, les fabricants se concentrant de plus en plus sur le développement de vaccins plus efficaces et plus stables. Montanide est l\'un des adjuvants de vaccins vétérinaires connus. La gamme d\'adjuvants Montanide repose sur trois technologies de base : les émulsions, les microémulsions et les polymères. Par conséquent, une augmentation des approbations d\'adjuvants pour les vaccins vétérinaires accélère la croissance globale du marché des adjuvants de vaccins.
Aperçu du marché européen des adjuvants de vaccins
Le marché européen des adjuvants de vaccins a été segmenté en Allemagne, Royaume-Uni, France, Italie, Espagne et reste de l\'Europe. Quelques grands fabricants de vaccins sont présents en Allemagne. En décembre 2022, Evonik a lancé un squalène d\'origine végétale appelé PhytoSquene pour améliorer l\'efficacité des vaccins. Il s\'agit d\'un dérivé non animal adapté aux vaccins et à d\'autres applications pharmaceutiques. PhytoSquene est le premier squalène dérivé de l\'huile d\'amarante connu introduit sur le marché pour les adjuvants dans les médicaments indiqués pour une utilisation parentérale. Cette dernière innovation d\'Evonik est destinée à fournir au marché des solutions durables et non dérivées d\'animaux. En 2021, Evonik a lancé le cholestérol de qualité pharmaceutique et d\'origine végétale « PhytoChol ».
Chiffre d\'affaires et prévisions du marché européen des adjuvants de vaccins jusqu\'en 2030 (en millions de dollars américains)
Segmentation du marché européen des adjuvants de vaccins
Le marché européen des adjuvants de vaccins est classé en classe d\'adjuvant, type et pays.
Sur la base de la classe d\'adjuvant, le marché européen des adjuvants de vaccins est segmenté en adjuvant de sel minéral, adjuvant d\'émulsion, adjuvant de liposome et autres. Le segment des adjuvants de sel minéral détenait la plus grande part de marché des adjuvants de vaccins en Europe en 2022.
Par type, le marché européen des adjuvants de vaccins est divisé en adjuvant de vaccin humain et adjuvant de vaccin vétérinaire. Le segment des adjuvants de vaccins humains détenait une part plus importante du marché européen des adjuvants de vaccins en 2022.
Par pays, le vaccin européen Le marché des adjuvants vaccinaux est segmenté en Allemagne, au Royaume-Uni, en France, en Italie, en Espagne et dans le reste de l\'Europe. L\'Allemagne a dominé la part de marché des adjuvants vaccinaux en Europe en 2022.
Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; et SPI Pharma Inc sont quelques-unes des principales sociétés opérant sur le marché européen des adjuvants vaccinaux.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Vaccine Adjuvants Market – Key Market Dynamics
4.1 Europe Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:
5. Vaccine Adjuvants Market –Europe Market Analysis
5.1 Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
5.2 Europe Vaccine Adjuvants Market Forecast and Analysis
6. Europe Vaccine Adjuvants Market Analysis – by Adjuvant Class
6.1 Overview
6.2 Mineral Salt Adjuvant
6.2.1 Overview
6.2.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
6.3.1 Overview
6.3.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
6.4.1 Overview
6.4.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Europe Vaccine Adjuvants Market Analysis – by Type
7.1 Human Vaccine Adjuvant
7.1.1 Overview
7.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
7.2.1 Overview
7.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Vaccine Adjuvants Market –Country Analysis
8.1 Europe
8.1.1 Europe Vaccine Adjuvants Market
8.1.1.1 Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 Germany: Glucose Monitoring Devices Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.3 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.4 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.1 Overview
8.1.1.4.2 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.5 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.1 Overview
8.1.1.5.2 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.6 Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.1 Overview
8.1.1.6.2 Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.3 Rest of Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.6.4 Rest of Europe Vaccine Adjuvants Market Breakdown, by Type
9. Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
9.3.1 Overview
9.4 Inorganic Developments
9.4.1 Overview
10. Company Profiles
10.1 SPI Pharma Inc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 GSK Plc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 CSL Ltd
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Seppic SA
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Dynavax Technologies Corp
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 InvivoGen SAS
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Croda International Plc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Novavax Inc
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Phibro Animal Health Corp
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
List of Tables
Table 1. Europe Vaccine Adjuvants Market Segmentation
Table 2. Europe Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
Table 3. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 4. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 5. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 6. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 8. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 9. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 10. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 12. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 14. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 15. Organic Developments Done by Companies
Table 16. Inorganic Developments Done by Companies
List of Figures
Figure 1. Europe Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 4. Europe Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 5. Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 10. Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Europe Vaccine Adjuvants Market – Revenue by Key Countries Revenue 2022 (US$ Million)
Figure 13. Europe Vaccine Adjuvants Market (2022 and 2030)
Figure 14. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 15. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 16. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 17. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 18. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 19. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 20. Growth Strategies in the Vaccine Adjuvants Market
- SPI Pharma Inc
- GSK Plc
- CSL Ltd
- Seppic SA
- Dynavax Technologies Corp
- InvivoGen SAS
- Croda International Plc
- Novavax Inc
- Phibro Animal Health Corp
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe vaccine adjuvants market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.